Archives
- 2018-07
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
Lorlatinib is an orally active brain penetrant
2023-07-16
Lorlatinib is an orally active brain penetrant cyclic 2-aminopyridine derivative that is a type I½ B ALK inhibitor (Fig. 5F) [61]. This medicinal is an effective antagonist against the more common L1196M and G1269A crizotinib-resistant mutations as well as the less common T1151Ins, L1152R, C1156Y, F
-
br Development of lorlatinib from crizotinib
2023-07-16
Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
-
br Study approval br Author
2023-07-16
Study approval Author contributions Conflicts of interest Acknowledgements This work was supported by grants of the Youth Backbone Program (to Jianming Ying) of Cancer Hospital, CAMS, Beijing, Beijing Hope Run Special Fund of Cancer Foundation of China (LC2015A06) and the National Natura
-
br Conclusion br Introduction Lung cancer is the
2023-07-16
Conclusion Introduction Lung cancer is the principal cause of death by cancer and the third most common cancer worldwide (Sorber et al., 2016). Lung cancer has two main types: small cell carcinomas (approximately 20%) and non-small cell lung cancers (NSCLC) (about 80%) (Fan et al., 2016). NSC
-
Among all the compounds the novel L derivative d
2023-07-16
Among all the compounds, the novel L-748,337 derivative (23d) showed the potent human β3-AR antagonist activity and high lipolysis inhibitory activity in vitro. The amoxicillin price 23d displayed 23-fold more potent β3-AR antagonist activity (EC50 = 0.5117 nM) than that of L-748,337 (EC50 = 11.91 n
-
The synthetic adipoR agonists AdipoRon and are both detectab
2023-07-16
The synthetic adipoR agonists, AdipoRon (1) and 112254 (2), are both detectable in human plasma [18]. However, with increasing knowledge about their metabolism [19], a method for detection from human urine is conceivable and would be preferred given the easier accessibility and greater frequency of
-
br Acknowledgments br Introduction Within
2023-07-16
Acknowledgments Introduction Within the classical secretory pathway, transmembrane and soluble cargos travel via the endoplasmic reticulum (ER) and Golgi apparatus en route to their final destinations [1]. However, at a post-Golgi level, trafficking routes can diverge. In this context, the tra
-
Based on the observation that
2023-07-16
Based on the observation that antipsychotic drugs increase 5-HT1A–D2 heteromerization level (Łukasiewicz et al., 2016), we set out to compare the effect of paroxetine to that of risperidone. Paroxetine, a potent SSRI, is very effective in the treatment of depression and anxiety disorders, e.g., gene
-
The fact that the BPloopAsn regains its Btx binding
2023-07-16
The fact that the α1-BPloopAsn141 regains its α-Btx binding with a Kd similar to that of the wild type α1 ECD [18], suggests that the AChBP Cys-loop does not interfere with the correct conformation of the mutant ECD. Data from analogous mutants of the human neuronal α7 subunit ECD showed improved li
-
To date more than different mutations
2023-07-16
To date, more than 50 different mutations in the gene have been described (Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff: SRD5A2 Gene: http://www.hgmd.cf.ac.uk). Most of them are missense mutations but premature stop codons and deletions leading to non-functional or su
-
Our previous studies found that some
2023-07-16
Our previous studies found that some steroid mimetic structures such as stilbene, biphenyl, naphthalene and benzothiophene rings were suitable for lipophilic moieties of 17,20-lyase inhibitors, and several inhibitors obtained using a steroid A, C-ring mimetic approach have already been published. Du
-
br Conclusions br Acknowledgments br Introduction To die or
2023-07-16
Conclusions Acknowledgments Introduction To die or not to die – that is the question. Christian de Duve created the word “autophagy” in 1960’s for the first time (Klionsky et al., 2016). The word “autophagy” was derived from the Greek roots “auto” (self) and “phagy” (eating) and referred to
-
br Conclusions The present protocol for
2023-07-16
Conclusions The present protocol for localizing or “spotting” the site of action of an antioxidant in a micro-heterogeneous medium is based on the differences in its reactivity vis-à-vis the series of amphiphobic TEMPO derivatives 1a–f. Plots of the relative antioxidant effectiveness of a given
-
Based on structure activity relationship of several SARM
2023-07-15
Based on structure activity relationship of several SARM templates, Ligand Pharmaceuticals chose LGD2226 as their first clinical candidate (Miner et al., 2007). Although LGD2226 demonstrated myo- and osteo-anabolic activity and maintenance of sexual function in various preclinical models, the develo
-
What is the mechanism by which Wnt a Fz signaling
2023-07-15
What is the mechanism by which Wnt7a-Fz7 signaling enhances AMPAR localization and synaptic strength? Following induction of LTP, the number of AMPARs rapidly increases at extrasynaptic sites (Makino and Malinow, 2009, Yang et al., 2008a) through PKA-dependent phosphorylation of GluA1 at S845 (He et
14914 records 297/995 page Previous Next First page 上5页 296297298299300 下5页 Last page